Niederer Kraft Frey advised Capvis, the specialist in mid-market investments and a well-known Swiss investor, on the investment into AdEx Partners. The growth strategy will be further enhanced through expansion of the service portfolio, internationalization, and m&a. The existing management team and partners will continue to be invested alongside Capvis. AdEx Partners, is a leading […]
On January 5, 2023, BioVersys announced that the AMR Action Fund has joined existing investors of BioVersys, extending the total proceeds of the Series C round to CHF 32.6 million. The Swiss pharma company represents the first European-based
The first edition of “Mergers & Acquisitions” co-edited by Florian S. Jörg (partner at Bratschi, pictured left), Urs Gnos (partner at Walder Wyss, pictured center) and Schellenberg Wittmer corporate/m&a partner Lorenzo
CVC and Partners Group have entered into an agreement for Partners Group to increase its stake in leading Swiss watchmaker Breitling in a transaction that will make it the company’s largest shareholder. Upon completion
As we have informed here NLS Pharmaceutics, a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system disorders, announced that it has
Investindustrial, a leading European group in the field of private equity, has signed an agreement through one of its investment vehicles for the entry of QuattroR into the capital of Medical Technology and Devices Group.
NLS Pharmaceutics, a Swiss clinical-stage biopharmaceutical company, has entered into a definitive agreement with BVF PARTNERS to raise aggregate gross proceeds of up to USD 30.0 million in a two-tranche private placement. The net proceeds will
Tandem Diabetes Care, a global insulin delivery and diabetes technology company, has announced that it has entered into a definitive agreement to acquire AMF Medical, the privately held Swiss developer of the Sigi™ Patch Pump,
The global innovation leader with technology-based materials and solutions, DuPont has divested the majority of its former Mobility & Materials segment to Celanese for a purchase price of $11 billion in cash, subject to customary transaction
As we have informed here last 10 November 2022, the clinical-stage biotechnology company Anokion has closed an USD 35 million equity investment from Pfizer through the Pfizer Breakthrough Growth Initiative. The Biotech company is focus on the treating
